FDA approves Jentadueto™ (linagliptin/metformin hydrochloride) tablets for the treatment of adult patients with type 2 diabetes
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…